
Foley partner Jana Kolarik is speaking at the Health Care Compliance Association’s (HCCA) 28th Annual Compliance Institute in a session titled “Stark Law & Valuation: Fixing Problematic Structures.” This session will cover:
- Refresher on valuation related to establishing fair market value,
- Compliance considerations regarding subsidy arrangements, and
- Stark Law issues related to work relative value unit (wRVU) models including advance practice practitioner (APP) work and tiered models.
For over two and a half decades, health care compliance professionals have gathered at HCCA’s Compliance Institute to share ideas, learn about the latest compliance issues, best practices, and emerging trends, and make key industry connections to drive compliance program and career success.
People
Related Insights
April 14, 2026
Health Care Law Today
FDA Clarifies Policies for Pharmacy Compounders of GLP-1 Products
On April 1, 2026,the U.S. Food & Drug Administration (FDA) issued a statement clarifying its compliance policy on the conditions that must be met for compounded drugs to qualify for the exemptions under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act).
April 14, 2026
Foley Career Perspectives
Trust Your Instincts: Susan Pravda on Leadership, Relationships, and Resilience
Foley partner Susan Pravda is a business lawyer focused on mergers and acquisitions, venture capital, initial public offerings, and related securities transactions and is head of Foley’s Health Care & Life Sciences Sector. She also serves as the firm’s chief strategic talent acquisition partner.
April 14, 2026
Blogs
When to Litigate and When to Walk Away
Clients faced with defending or initiating litigation often begin with the question: “Can we win?” The question sounds simple enough, and if the law is favorable, the instinctive answer might be “yes.” But “winning” in court doesn’t happen, and can’t be evaluated, in a vacuum. In reality, the odds of success in litigation depend not only on the law and facts of the case but also on any business constraints and potential consequences.